Guerbet acquires stake in Intrasense, plans tender offer
Medical imaging firm Guerbet has acquired a 39% stake in Intrasense and announced its intent to file a voluntary tender offer for the remaining shares at 0.44 euros per share.
Guerbet, a global player in medical imaging, has acquired a 39% stake in Intrasense for 8.8 million euros. The company announced on January 11, 2023, that it intends to launch a voluntary tender offer for the remaining Intrasense shares at a price of 0.44 euros per share.
The acquisition, which represents a 34.15% premium over Intrasense's last closing price, aligns with Guerbet's strategy to leverage its developed digital imaging technology and artificial intelligence algorithms. David Hale, CEO of Guerbet, stated that the partnership aims to enhance the integration of AI into the clinical routine for practitioners in imaging and oncology.
Intrasense specializes in medical imaging software solutions that aid diagnosis, decision-making, and therapeutic follow-up. Guerbet, already a leader in medical imaging, has been diversifying into digital sectors, developing AI algorithms for detecting liver lesions, prostate and pancreatic cancers, and bone metastases.
This move is expected to enable Intrasense to expand its product offerings and benefit from the support of a major shareholder for its growth plan. Guerbet anticipates enhancing the value of its own technologies and AI algorithms. The companies also plan to enter into a licensing agreement in early 2023, allowing Intrasense to integrate Guerbet's AI algorithms into its software platforms.